{"transactions":[{"id":3453455,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-07-30T20:03:45.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents shares of Company common stock underlying compensatory options to purchase shares of Company common stock, whether or not vested and which have a per share exercise price that is less than $48.00 (each, an \"In the Money Option\"). Pursuant to the terms of the Merger Agreement, each In the Money Option held by the Reporting Person was cancelled and converted into the right to a cash payment equal to (i) the excess, if any, of (A) $48.00 over (B) the exercise price payable per share of Company common stock under such In the Money Option, multiplied by (ii) the total number of shares of Company common stock subject to such In the Money Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option provided for vesting in four equal annual installments beginning on October 25, 2019."}],"balance_after":0,"derivative":{"exercise_price":14.55,"expiration_date":"2028-10-25","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-19-043780","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043780/doc4.xml","form_type":"4"}},{"id":3453454,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-30T20:03:45.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":30000,"price":48,"value":1440000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On June 14, 2019, the Company entered into a Merger Agreement with Pfizer and Purchaser. Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Held by BV Partners III Profit Sharing account for the benefit of the Reporting Person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-19-043780","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043780/doc4.xml","form_type":"4"}},{"id":3453453,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-30T20:03:45.000Z","date":"2019-07-30","kind":"other","acquired":false,"shares":15000,"price":48,"value":720000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On June 14, 2019, the Company entered into a Merger Agreement with Pfizer and Purchaser. Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Held by BV Partners III Profit Sharing account for the benefit of the Reporting Person."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001209191-19-043780","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043780/doc4.xml","form_type":"4"}},{"id":3453452,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-30T20:03:45.000Z","date":"2019-07-30","kind":"other","acquired":false,"shares":20000,"price":48,"value":960000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 14, 2019, Array BioPharma Inc. (the \"Company\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Pfizer Inc. (\"Pfizer\") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer (\"Purchaser\"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was validly tendered for $48.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held in trust for the benefit of the Reporting Person's minor children."}],"balance_after":45000,"source":{"system":"sec-edgar","filing":"0001209191-19-043780","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043780/doc4.xml","form_type":"4"}},{"id":3453451,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-30T20:03:45.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On June 14, 2019, the Company entered into a Merger Agreement with Pfizer and Purchaser. Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents shares of Company common stock underlying each restricted stock unit (a \"Company RSU\") held by the Reporting Person, whether or not vested. Pursuant to the terms of the Merger Agreement, each Company RSU held by the Reporting Person was converted into the right to receive an amount in cash equal to the product of (i) $48.00 and (ii) the number of shares of Company common stock subject to such Company RSU."}],"balance_after":65000,"source":{"system":"sec-edgar","filing":"0001209191-19-043780","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043780/doc4.xml","form_type":"4"}},{"id":3453450,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-30T20:03:45.000Z","date":"2019-07-30","kind":"disposition_to_issuer","acquired":false,"shares":85,"price":48,"value":4080.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."},{"field":"kind","element":"transactionCoding","label":"F3","text":"On June 14, 2019, the Company entered into a Merger Agreement with Pfizer and Purchaser. Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was cancelled and converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."}],"balance_after":70000,"source":{"system":"sec-edgar","filing":"0001209191-19-043780","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043780/doc4.xml","form_type":"4"}},{"id":3453449,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-07-30T20:03:45.000Z","date":"2019-07-30","kind":"other","acquired":false,"shares":22635,"price":48,"value":1086480.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On June 14, 2019, Array BioPharma Inc. (the \"Company\") entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Pfizer Inc. (\"Pfizer\") and Arlington Acquisition Sub Inc., a wholly owned subsidiary of Pfizer (\"Purchaser\"). Pursuant to the terms of the Merger Agreement, each share of Company common stock held by the Reporting Person was validly tendered for $48.00 per share in cash, without interest and subject to any required withholding of taxes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On July 30, 2019, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation and becoming a wholly-owned subsidiary of Pfizer. Pursuant to the terms of the Merger Agreement, each share of Company common stock was converted into the right to receive an amount in cash equal to $48.00, without interest and subject to any required withholding of taxes."}],"balance_after":70085,"source":{"system":"sec-edgar","filing":"0001209191-19-043780","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919119043780/doc4.xml","form_type":"4"}},{"id":3668778,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-02-08T19:14:30.000Z","date":"2019-02-06","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The options vested on October 26, 2018."}],"balance_after":0,"derivative":{"exercise_price":10.47,"expiration_date":"2027-10-26","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-19-000863","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019000863/primarydocument.xml","form_type":"4"}},{"id":3668777,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-08T19:14:30.000Z","date":"2019-02-06","kind":"sale","acquired":false,"shares":5000,"price":20.8522,"value":104261.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sale was made by the Reporting Person as custodian for his son under the Colorado Uniform Gifts to Minors Act."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported for these shares is the weighted average sale price of transactions made at prices from $20.805 to $20.864. Details of actual prices for shares sold are available from the Reporting Person upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Comprised of shares of common stock in trust for the benefit of the Reporting Person's minor children."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001562180-19-000863","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019000863/primarydocument.xml","form_type":"4"}},{"id":3668776,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-08T19:14:30.000Z","date":"2019-02-06","kind":"sale","acquired":false,"shares":5000,"price":20.8241,"value":104120.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The sale was made by the Reporting Person as custodian for his son under the Colorado Uniform Gifts to Minors Act."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported for these shares is the weighted average sale price of transactions made at prices from $20.785 to $20.834. Details of actual prices for shares sold are available from the Reporting Person upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Comprised of shares of common stock in trust for the benefit of the Reporting Person's minor children."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001562180-19-000863","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019000863/primarydocument.xml","form_type":"4"}},{"id":3668775,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-08T19:14:30.000Z","date":"2019-02-06","kind":"sale","acquired":false,"shares":25000,"price":20.5077,"value":512692.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported for these shares is the weighted average sale price of transactions made at prices from $20.50 to $20.58. Details of actual prices for shares sold are available from the Reporting Person upon request."}],"balance_after":22720,"source":{"system":"sec-edgar","filing":"0001562180-19-000863","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019000863/primarydocument.xml","form_type":"4"}},{"id":3668774,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-02-08T19:14:30.000Z","date":"2019-02-06","kind":"exercise","acquired":true,"shares":25000,"price":10.47,"value":261750.0,"ownership":{"direct":true},"balance_after":47720,"source":{"system":"sec-edgar","filing":"0001562180-19-000863","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218019000863/primarydocument.xml","form_type":"4"}},{"id":3781733,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-10-29T18:10:08.000Z","date":"2018-10-26","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vested and were settled in common stock on October 26, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs vested and were settled in common stock on October 26, 2018."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001562180-18-004315","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018004315/primarydocument.xml","form_type":"4"}},{"id":3781732,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2018-10-29T18:10:08.000Z","date":"2018-10-25","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"RSUs awarded to the reporting person for no additional cash consideration and each represents a contingent right to receive one share of common stock.  The RSUs vest in full and will be settled in common stock on October 25, 2019, subject to continued service on Array's board of directors."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs awarded to the reporting person for no additional cash consideration and each represents a contingent right to receive one share of common stock.  The RSUs vest in full and will be settled in common stock on October 25, 2019, subject to continued service on Array's board of directors."}],"balance_after":5000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001562180-18-004315","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018004315/primarydocument.xml","form_type":"4"}},{"id":3781731,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-10-29T18:10:08.000Z","date":"2018-10-25","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest in full on October 25, 2019, subject to continued service on Array's board of directors."}],"balance_after":25000,"derivative":{"exercise_price":14.55,"expiration_date":"2028-10-25","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-18-004315","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018004315/primarydocument.xml","form_type":"4"}},{"id":3781730,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-29T18:10:08.000Z","date":"2018-10-26","kind":"exercise","acquired":true,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued upon settlement of Restricted Stock Units (\"RSUs\") granted by Array BioPharma Inc. (\"Array\") on October 26, 2017, as a result of the vesting of all such RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares issued upon settlement of Restricted Stock Units (\"RSUs\") granted by Array BioPharma Inc. (\"Array\") on October 26, 2017, as a result of the vesting of all such RSUs."}],"balance_after":22720,"source":{"system":"sec-edgar","filing":"0001562180-18-004315","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018004315/primarydocument.xml","form_type":"4"}},{"id":3840463,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-08-17T16:46:06.000Z","date":"2016-11-28","kind":"gift","acquired":false,"shares":2085,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The gift of shares was originally listed as 2,000 shares instead of the 2,085 shares actually gifted."}],"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001562180-18-003681","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018003681/primarydocument.xml","form_type":"4/A","original_submission_date":"2017-04-04"}},{"id":3871914,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-07-06T16:06:53.000Z","date":"2018-07-06","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":5.95,"exercise_date":"2016-10-27","expiration_date":"2025-10-27","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-18-041857","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919118041857/doc4.xml","form_type":"4"}},{"id":3871913,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-07-06T16:06:53.000Z","date":"2018-07-06","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":5.13,"exercise_date":"2015-10-29","expiration_date":"2024-10-29","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-18-041857","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919118041857/doc4.xml","form_type":"4"}},{"id":3871912,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-06T16:06:53.000Z","date":"2018-07-06","kind":"sale","acquired":false,"shares":50000,"price":17.45,"value":872500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported for these shares is the weighted average sale price of transactions made at prices from $17.45 to $17.461. Details of actual prices for shares sold are available from the Issuer upon request."}],"balance_after":17720,"source":{"system":"sec-edgar","filing":"0001209191-18-041857","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919118041857/doc4.xml","form_type":"4"}},{"id":3871911,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-06T16:06:53.000Z","date":"2018-07-06","kind":"exercise","acquired":true,"shares":25000,"price":5.95,"value":148750.0,"ownership":{"direct":true},"balance_after":67720,"source":{"system":"sec-edgar","filing":"0001209191-18-041857","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919118041857/doc4.xml","form_type":"4"}},{"id":3871910,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-07-06T16:06:53.000Z","date":"2018-07-06","kind":"exercise","acquired":true,"shares":25000,"price":5.13,"value":128250.0,"ownership":{"direct":true},"balance_after":42720,"source":{"system":"sec-edgar","filing":"0001209191-18-041857","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000120919118041857/doc4.xml","form_type":"4"}},{"id":4066438,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-12T17:27:33.000Z","date":"2018-02-09","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":3.87,"exercise_date":"2015-10-30","expiration_date":"2024-10-30","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-18-000729","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018000729/primarydocument.xml","form_type":"4"}},{"id":4066437,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-02-12T17:27:33.000Z","date":"2018-02-09","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":5.6,"exercise_date":"2014-10-23","expiration_date":"2023-10-23","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-18-000729","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018000729/primarydocument.xml","form_type":"4"}},{"id":4066436,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-12T17:27:33.000Z","date":"2018-02-09","kind":"sale","acquired":false,"shares":50000,"price":17.01,"value":850500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request."}],"balance_after":17720,"source":{"system":"sec-edgar","filing":"0001562180-18-000729","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018000729/primarydocument.xml","form_type":"4"}},{"id":4066435,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-12T17:27:33.000Z","date":"2018-02-09","kind":"exercise","acquired":true,"shares":25000,"price":3.87,"value":96750.0,"ownership":{"direct":true},"balance_after":67720,"source":{"system":"sec-edgar","filing":"0001562180-18-000729","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018000729/primarydocument.xml","form_type":"4"}},{"id":4066434,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-02-12T17:27:33.000Z","date":"2018-02-09","kind":"exercise","acquired":true,"shares":25000,"price":5.6,"value":140000.0,"ownership":{"direct":true},"balance_after":42720,"source":{"system":"sec-edgar","filing":"0001562180-18-000729","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218018000729/primarydocument.xml","form_type":"4"}},{"id":4179587,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-10-27T16:32:42.000Z","date":"2017-10-27","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs awarded to the reporting person on October 27, 2016 for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The units vested and were settled in stock on October 27, 2017."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2017-10-27","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001562180-17-003345","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003345/primarydocument.xml","form_type":"4"}},{"id":4179586,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2017-10-27T16:32:42.000Z","date":"2017-10-26","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":". RSUs awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The units vest and will be settled in stock on October 26, 2018, subject to continued service on Array's board of directors."}],"balance_after":5000,"derivative":{"exercise_price":0,"exercise_date":"2018-10-26","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001562180-17-003345","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003345/primarydocument.xml","form_type":"4"}},{"id":4179585,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-10-27T16:32:42.000Z","date":"2017-10-26","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":10.47,"exercise_date":"2018-10-26","expiration_date":"2027-10-26","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-17-003345","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003345/primarydocument.xml","form_type":"4"}},{"id":4179584,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-10-27T16:32:42.000Z","date":"2017-10-27","kind":"exercise","acquired":true,"shares":5000,"price":10.47,"value":52350.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued upon settlement of Restricted Stock Units (\"RSUs\") granted by the Issuer on October 27, 2016 as a result of the vesting of all such RSUs."}],"balance_after":17720,"source":{"system":"sec-edgar","filing":"0001562180-17-003345","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003345/primarydocument.xml","form_type":"4"}},{"id":4199253,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-09-29T18:22:42.000Z","date":"2017-09-29","kind":"exercise","acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 is reporting the exercise by the reporting person of an option scheduled to expire on November 1, 2017 and the sale of a portion of the option shares to satisfy payment of the option exercise price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested in 3 equal annual installments beginning on November 1, 2008."}],"balance_after":0,"derivative":{"exercise_price":10.58,"exercise_date":"2010-11-01","expiration_date":"2017-11-01","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001562180-17-003064","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003064/primarydocument.xml","form_type":"4"}},{"id":4199252,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-29T18:22:42.000Z","date":"2017-09-29","kind":"sale","acquired":false,"shares":38865,"price":12.31,"value":478428.15,"ownership":{"direct":true},"balance_after":12720,"source":{"system":"sec-edgar","filing":"0001562180-17-003064","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003064/primarydocument.xml","form_type":"4"}},{"id":4199251,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-09-29T18:22:42.000Z","date":"2017-09-29","kind":"exercise","acquired":true,"shares":45000,"price":10.58,"value":476100.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 is reporting the exercise by the reporting person of an option scheduled to expire on November 1, 2017 and the sale of a portion of the option shares to satisfy payment of the option exercise price."}],"balance_after":51585,"source":{"system":"sec-edgar","filing":"0001562180-17-003064","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017003064/primarydocument.xml","form_type":"4"}},{"id":4269053,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2017-06-30T17:24:56.000Z","date":"2017-06-28","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Automatic non-discretionary grant to the Reporting Person of a nonstatutory stock option under the Issuer's 2016 Equity Incentive Plan (the \"Plan\") in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy. One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one-year anniversary of the date of grant or (ii) the date of the next annual meeting of the Issuer's stockholders following the date of grant, subject in each case to the Reporting Person's continued service on such vesting date."}],"balance_after":12000,"derivative":{"exercise_price":12.06,"expiration_date":"2027-06-27","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-17-042575","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191818/000120919117042575/doc4.xml","form_type":"4"}},{"id":4362036,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-04-04T21:41:17.000Z","date":"2017-03-31","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":4.36,"exercise_date":"2013-10-24","expiration_date":"2022-10-24","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001562180-17-001461","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017001461/primarydocument.xml","form_type":"4"}},{"id":4362035,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2017-04-04T21:41:17.000Z","date":"2017-03-31","kind":"exercise","acquired":false,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vested in 2 equal annual installments beginning on April 25, 2013."}],"balance_after":0,"derivative":{"exercise_price":3.69,"expiration_date":"2022-04-25","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-17-001461","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017001461/primarydocument.xml","form_type":"4"}},{"id":4362034,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-04-04T21:41:17.000Z","date":"2017-03-31","kind":"sale","acquired":false,"shares":45000,"price":8.92,"value":401400.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request."}],"balance_after":6585,"source":{"system":"sec-edgar","filing":"0001562180-17-001461","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017001461/primarydocument.xml","form_type":"4"}},{"id":4362033,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-04-04T21:41:17.000Z","date":"2017-03-31","kind":"exercise","acquired":true,"shares":20000,"price":4.36,"value":87200.0,"ownership":{"direct":true},"balance_after":51585,"source":{"system":"sec-edgar","filing":"0001562180-17-001461","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017001461/primarydocument.xml","form_type":"4"}},{"id":4362032,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-04-04T21:41:17.000Z","date":"2017-03-31","kind":"exercise","acquired":true,"shares":25000,"price":3.69,"value":92250.0,"ownership":{"direct":true},"balance_after":31585,"source":{"system":"sec-edgar","filing":"0001562180-17-001461","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017001461/primarydocument.xml","form_type":"4"}},{"id":4362031,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-04-04T21:41:17.000Z","date":"2016-11-28","kind":"gift","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6585,"source":{"system":"sec-edgar","filing":"0001562180-17-001461","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218017001461/primarydocument.xml","form_type":"4"}},{"id":4388418,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-13T18:37:48.000Z","date":"2017-03-10","kind":"sale","acquired":false,"shares":3300,"price":14.3118,"value":47228.94,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.96 to $14.645, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All of the shares are held by Boulder Ventures VI, L.P. (\"BV VI LP\"). BV Partners VI, LLC (\"BV VI LLC\"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":463473,"source":{"system":"sec-edgar","filing":"0001209191-17-020291","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1191818/000120919117020291/doc4.xml","form_type":"4"}},{"id":4388417,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-13T18:37:48.000Z","date":"2017-03-09","kind":"sale","acquired":false,"shares":2500,"price":14.3846,"value":35961.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All of the shares are held by Boulder Ventures VI, L.P. (\"BV VI LP\"). BV Partners VI, LLC (\"BV VI LLC\"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":466773,"source":{"system":"sec-edgar","filing":"0001209191-17-020291","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191818/000120919117020291/doc4.xml","form_type":"4"}},{"id":4394552,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-08T17:12:10.000Z","date":"2017-03-08","kind":"sale","acquired":false,"shares":5000,"price":14.7028,"value":73514.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.48 to $15.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All of the shares are held by Boulder Ventures VI, L.P. (\"BV VI LP\"). BV Partners VI, LLC (\"BV VI LLC\"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":469273,"source":{"system":"sec-edgar","filing":"0001209191-17-019319","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1191818/000120919117019319/doc4.xml","form_type":"4"}},{"id":4394551,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-08T17:12:10.000Z","date":"2017-03-06","kind":"sale","acquired":false,"shares":608,"price":16.2398,"value":9873.7984,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.21 to $16.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All of the shares are held by Boulder Ventures VI, L.P. (\"BV VI LP\"). BV Partners VI, LLC (\"BV VI LLC\"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":474273,"source":{"system":"sec-edgar","filing":"0001209191-17-019319","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1191818/000120919117019319/doc4.xml","form_type":"4"}},{"id":4394550,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-03-08T17:12:10.000Z","date":"2017-03-06","kind":"sale","acquired":false,"shares":9392,"price":15.7144,"value":147589.6448,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.20 to $16.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All of the shares are held by Boulder Ventures VI, L.P. (\"BV VI LP\"). BV Partners VI, LLC (\"BV VI LLC\"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":474881,"source":{"system":"sec-edgar","filing":"0001209191-17-019319","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191818/000120919117019319/doc4.xml","form_type":"4"}},{"id":4417104,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-02-28T18:52:36.000Z","date":"2017-02-28","kind":"sale","acquired":false,"shares":2258,"price":13.543,"value":30580.094,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All of the shares are held by Boulder Ventures VI, L.P. (\"BV VI LP\"). BV Partners VI, LLC (\"BV VI LLC\"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":484273,"source":{"system":"sec-edgar","filing":"0001209191-17-015457","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1191818/000120919117015457/doc4.xml","form_type":"4"}},{"id":4417103,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-02-28T18:52:36.000Z","date":"2017-02-27","kind":"sale","acquired":false,"shares":1500,"price":13.791,"value":20686.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.75 to $13.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All of the shares are held by Boulder Ventures VI, L.P. (\"BV VI LP\"). BV Partners VI, LLC (\"BV VI LLC\"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":486531,"source":{"system":"sec-edgar","filing":"0001209191-17-015457","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1191818/000120919117015457/doc4.xml","form_type":"4"}},{"id":4417102,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-02-28T18:52:36.000Z","date":"2017-02-24","kind":"sale","acquired":false,"shares":6500,"price":14.0388,"value":91252.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All of the shares are held by Boulder Ventures VI, L.P. (\"BV VI LP\"). BV Partners VI, LLC (\"BV VI LLC\"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":488031,"source":{"system":"sec-edgar","filing":"0001209191-17-015457","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191818/000120919117015457/doc4.xml","form_type":"4"}},{"id":4424209,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-02-24T19:07:16.000Z","date":"2017-02-23","kind":"sale","acquired":false,"shares":1800,"price":13.6477,"value":24565.86,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $14.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All of the shares are held by Boulder Ventures VI, L.P. (\"BV VI LP\"). BV Partners VI, LLC (\"BV VI LLC\"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":494531,"source":{"system":"sec-edgar","filing":"0001209191-17-014537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1191818/000120919117014537/doc4.xml","form_type":"4"}},{"id":4424208,"issuer":{"id":4316,"kind":"organization","name":"Viridian Therapeutics, Inc.\\DE"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-02-24T19:07:16.000Z","date":"2017-02-22","kind":"sale","acquired":false,"shares":4102,"price":14.3554,"value":58885.8508,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.28 to $14.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the ranges set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"All of the shares are held by Boulder Ventures VI, L.P. (\"BV VI LP\"). BV Partners VI, LLC (\"BV VI LLC\"), the general partner of BV VI LP may be deemed to indirectly beneficially own the shares. Kyle A. Lefkoff, Peter A. Roshko and Jonathan L. Perl are managing members of BV VI LLC, and each share voting and dispositive power over the shares held by BV VI LP. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein, if any."}],"balance_after":496331,"source":{"system":"sec-edgar","filing":"0001209191-17-014537","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1191818/000120919117014537/doc4.xml","form_type":"4"}},{"id":4572125,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2016-10-31T19:15:18.000Z","date":"2016-10-29","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs awarded to the reporting person on October 29, 2015 for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The units vested and were settled in stock on October 29, 2016."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2016-10-29","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001562180-16-003297","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218016003297/primarydocument.xml","form_type":"4"}},{"id":4572124,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2016-10-31T19:15:18.000Z","date":"2016-10-27","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":25000,"derivative":{"exercise_price":5.95,"exercise_date":"2017-10-27","expiration_date":"2026-10-27","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-16-003297","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218016003297/primarydocument.xml","form_type":"4"}},{"id":4572123,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2016-10-31T19:15:18.000Z","date":"2016-10-27","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"RSUs awarded to the reporting person for no additional cash consideration and represent a contingent right to receive one share of Array BioPharma Inc. common stock. The units vest and will be settled in stock on October 27, 2017, subject to continued service on Array's board of directors."}],"balance_after":5000,"derivative":{"exercise_price":0,"exercise_date":"2017-10-27","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001562180-16-003297","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218016003297/primarydocument.xml","form_type":"4"}},{"id":4572122,"issuer":{"id":155788,"kind":"organization","name":"ARRAY BIOPHARMA INC","symbol":"ARRY"},"owners":[{"id":155789,"kind":"person","name":"LEFKOFF KYLE","position":1,"cik":"0001191818","reported_name":"LEFKOFF KYLE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2016-10-31T19:15:18.000Z","date":"2016-10-29","kind":"exercise","acquired":true,"shares":5000,"price":5.83,"value":29150.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares issued upon settlement of Restricted Stock Units (\"RSUs\") granted by the Issuer on October 29, 2015 as a results of the vesting of all such RSUs."}],"balance_after":8585,"source":{"system":"sec-edgar","filing":"0001562180-16-003297","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1100412/000156218016003297/primarydocument.xml","form_type":"4"}}]}